Contributors

About the Authors

  • The Authors of "Patent Docs" are patent attorneys who hold doctorates in a diverse array of biotech and chemical disciplines.

Contact the Docs

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter. When a new article is posted during the day, you will receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

« Patenting Life (Really) | Main | Patent Profile: Merrimack Pharmaceuticals Announces Issuance of Recombinant, Non-Glycosylated Human Alpha-fetoprotein Patent »

June 11, 2007

Court Report

    By Sherri Oslick --

Gavel_2About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.


Pfizer Inc. et al v. Teva Pharmaceuticals USA Inc.

1:07-cv-00360; filed June 7, 2007 in the District Court of Delaware

Infringement of U.S. Patent No. 5,273,995 ("[R-(R*R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof," issued December 28, 1993) based on Teva's filing of an ANDA to manufacture a generic version of Pfizer's Lipitor® (atorvastatin calcium, used to treat high cholesterol and heart disease).  View the complaint here.


Purdue Pharma L.P. et al v. KV Pharmaceutical Company

1:07-cv-04810; filed June 6, 2007 in the Southern District of New York

Infringement of U.S. Patent Nos. 5,508,042 ("Controlled Release Oxycodone Compositions," issued April 16, 1996), 5,549,912 (same title, issued August 27, 1996), and 5,656,295 (same title, issued August 12, 1997) following a paragraph IV certification as part of KV's and Actavis' filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/t/trackback/1117334/19235496

Listed below are links to weblogs that reference Court Report:

Comments

Post a comment

May 2008

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Google Search